| 1 |
34025432 | Effects of Antiarrhythmic Drugs on hERG Gating in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1. | 2021 |
1 |
| 2 |
31169990 | Pharmacological Profile of the Bradycardic Agent Ivabradine on Human Cardiac Ion Channels. | 2019 |
1 |
| 3 |
29806042 | Performance of Machine Learning Algorithms for Qualitative and Quantitative Prediction Drug Blockade of hERG1 channel. | 2018 May |
1 |
| 4 |
28556923 | Antiarrhythmic properties of ivabradine in an experimental model of Short-QT- Syndrome. | 2017 Sep |
1 |
| 5 |
25911606 | hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine. | 2015 Apr 24 |
2 |
| 6 |
25986146 | Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCN4. | 2015 Aug |
3 |
| 7 |
26275355 | hERG potassium channel inhibition by ivabradine requires channel gating. | 2015 Oct |
1 |
| 8 |
26301071 | hERG potassium channel inhibition by ivabradine may contribute to QT prolongation and risk of torsades de pointes. | 2015 Aug |
1 |